Axsome Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its oral drug for the treatment of depression in adults, sending its shares up 17% in premarket trading. The company faced a delay in getting the agency’s approval for the drug last year…
New Depression Drug Gets FDA Approval

Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering
Imagine waiting in line for a new ride at an amusement park, anxious and excited. You finally get on the ride, and to your surprise, the thrilling experience starts right away! That’s exactly what Axsome Therapeutics’ newly FDA-approved drug is like for adults with depression. With its oral form, this medication aims to provide relief in just one week, offering a faster solution than traditional treatments. The FDA’s approval is a big win for the company after facing a delay last year. This groundbreaking drug could potentially revolutionize the way we treat depression, opening doors to improved mental health and well-being. Now, individuals struggling with depression have a ray of hope shining down on them! If you or someone you know is affected by depression, it’s worth exploring this exciting advancement in pharmaceutical research.